# Combination Cancer Therapy and Reference Models for Assessing Drug Synergy in Glioblastoma

## TL;DR

This paper reviews current and emerging glioblastoma treatments, focusing on combination therapies and models to assess drug synergy for better patient outcomes.

## Contribution

The paper provides a comprehensive review and critical evaluation of reference models for assessing drug synergy in glioblastoma combination therapies.

## Key findings

- Combination therapies are essential for improving glioblastoma treatment outcomes.
- Accurate reference models are crucial for interpreting drug synergy across preclinical and clinical stages.
- Mechanistic understanding and improved modeling can accelerate clinical translation of combination therapies.

## Abstract

This review provides an overview of current and emerging glioblastoma treatment approaches, with particular attention to combination therapies and the reference models used to assess their effectiveness. Identifying true synergistic effects between therapeutic agents is critical for improving patient outcomes. Properly designed reference models that reflect the mechanisms of action across preclinical and clinical stages can significantly enhance the interpretation of experimental data. A deeper mechanistic understanding and more accurate modeling will ultimately accelerate the translation of promising combination therapies into effective clinical strategies for managing malignant gliomas.

Glioblastoma is currently an incurable disease despite the development of a wide variety of therapeutic approaches, from surgical methods to immunotherapy. In current clinical practice, treatment typically involves a combination of existing methods, often comprising three stages: tumor resection, radiotherapy, and chemotherapy. Modern research offers improved chemotherapy strategies, as well as combinations of chemotherapy with immunotherapy. However, the efficacy of these therapies is profoundly influenced by factors such as tumor and peritumoral heterogeneity, alongside complex molecular signaling pathways. Optimizing glioma treatment requires a rigorous mechanistic understanding of individual approaches and their synergistic effects. This review comprehensively details current glioblastoma therapeutic strategies and critically evaluates key reference models for assessing combination therapy efficacy and their inherent limitations. A deeper understanding of these mechanisms and models will refine the investigation of observed therapeutic effects and accelerate the translation of promising in vitro approaches to effective clinical management of malignant gliomas.